Literature DB >> 14734152

Inherited bleeding disorders: disorders of platelet adhesion and aggregation.

Indra Ramasamy1.   

Abstract

Platelet aggregation at sites of vascular injury is essential for the formation of the primary haemostatic plug. The mechanism of platelet aggregation under conditions of physiological flow is a complex multistep process, which requires the synergistic action of several different platelet receptors. Platelet interaction with collagen at sites of damage to the vascular endothelium involves adhesion, activation, secretion of platelet granular contents and finally aggregation. Other agonists other than collagen, such as fibrinogen, vWF and soluble agonists released from activated platelets (thromboxane A2 (TXA2) and ADP) are involved in platelet aggregation. Platelets express a variety of receptors including GP Ib-IX-V, GP VI, GP Ia-IIa and GP IIb-IIIa. One aspect of this complexity of function is the variety of inherited defects of platelet function. Hereditary disorders of platelet adhesion are Bernard-Soulier syndrome and von Willebrand disease. Glanzmann thrombasthenia is an inherited disorder of platelet aggregation. The application of molecular biology to the study of platelet disorders has identified defects in other collagen receptors, ADP receptors and TXA2 receptors. Defects affecting TXA2 production, the generation of procoagulant activity and secretion from dense bodies and alpha-granules are also encountered. Other rare diseases, Chediak-Higashi, Hermansky-Pudlak and Wiskott-Aldrich syndrome also affect platelet storage granules. In this article, recent advances in the understanding of platelet function and knowledge of inherited disorders that affect platelet adhesion and aggregation is reviewed. As progress advances towards individualisation of therapy the phenotypic bleeding tendency of each patient becomes relevant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734152     DOI: 10.1016/s1040-8428(03)00117-3

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  13 in total

1.  Enzymes that hydrolyze adenine nucleotides in platelets and polymorphisms in the alpha2 gene of integrin alpha2beta1 in patients with von Willebrand disease.

Authors:  Karen Freitas Santos; Vanessa Battisti; Maísa de Carvalho Corrêa; Thaís Rapachi Mann; Renata da Silva Pereira; Maria do Carmo Araújo; Alice Odete Brülê; Maria Rosa Chitolina Schetinger; Vera Maria Morsch
Journal:  Mol Cell Biochem       Date:  2010-03-25       Impact factor: 3.396

2.  VAMP-7 links granule exocytosis to actin reorganization during platelet activation.

Authors:  Secil Koseoglu; Christian G Peters; Jennifer L Fitch-Tewfik; Omozuanvbo Aisiku; Lydia Danglot; Thierry Galli; Robert Flaumenhaft
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

3.  Antiplatelet activity of 3-butyl-6-bromo-1(3H)-isobenzofuranone on rat platelet aggregation.

Authors:  Feifei Ma; Yuan Gao; Hailing Qiao; Xiangjie Hu; Junbiao Chang
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

4.  Endobrevin/VAMP-8-dependent dense granule release mediates thrombus formation in vivo.

Authors:  Gwenda J Graham; Qiansheng Ren; James R Dilks; Price Blair; Sidney W Whiteheart; Robert Flaumenhaft
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 5.  SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?

Authors:  Susanne O Dalton; Henrik T Sørensen; Christoffer Johansen
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Use of a questionnaire to predict von Willebrand disease status and characterize hemorrhagic signs in a population of dogs and evaluation of a diagnostic profile to predict risk of bleeding.

Authors:  Hilary J Burgess; J Paul Woods; Anthony C G Abrams-Ogg; R Darren Wood
Journal:  Can J Vet Res       Date:  2009-10       Impact factor: 1.310

7.  Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function.

Authors:  Yingchun Wang; Eric Vachon; Jinyi Zhang; Vera Cherepanov; Joshua Kruger; Jun Li; Kan Saito; Patrick Shannon; Nunzio Bottini; Huong Huynh; Heyu Ni; Hong Yang; Colin McKerlie; Sue Quaggin; Zhizhuang Joe Zhao; Philip A Marsden; Tomas Mustelin; Katherine A Siminovitch; Gregory P Downey
Journal:  J Exp Med       Date:  2005-12-05       Impact factor: 14.307

8.  Understanding resolvin signaling pathways to improve oral health.

Authors:  David Keinan; Noel J Leigh; Joel W Nelson; Laura De Oleo; Olga J Baker
Journal:  Int J Mol Sci       Date:  2013-03-08       Impact factor: 5.923

Review 9.  What's new in using platelet research? To unravel thrombopathies and other human disorders.

Authors:  Kathleen Freson; Veerle Labarque; Chantal Thys; Christine Wittevrongel; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2007-07-10       Impact factor: 3.183

Review 10.  Biomechanics of haemostasis and thrombosis in health and disease: from the macro- to molecular scale.

Authors:  Reginald Tran; David R Myers; Jordan Ciciliano; Elaissa L Trybus Hardy; Yumiko Sakurai; Byungwook Ahn; Yongzhi Qiu; Robert G Mannino; Meredith E Fay; Wilbur A Lam
Journal:  J Cell Mol Med       Date:  2013-03-14       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.